Bristol-Myers Squibb (NYSE:BMY) Shares Down 0.5%

Bristol-Myers Squibb (NYSE:BMY)’s stock price was down 0.5% during trading on Friday . The stock traded as low as $48.65 and last traded at $48.86. Approximately 2,513,106 shares were traded during trading, a decline of 84% from the average daily volume of 15,872,297 shares. The stock had previously closed at $49.12.

Analyst Upgrades and Downgrades

BMY has been the subject of several recent research reports. Wells Fargo & Company decreased their price target on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $61.12.

Bristol-Myers Squibb Stock Down 1.7 %

The stock has a market cap of $97.85 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.51 and a beta of 0.39. The stock has a 50 day simple moving average of $51.28 and a 200 day simple moving average of $51.80. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. Bristol-Myers Squibb’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.82 EPS. As a group, analysts expect that Bristol-Myers Squibb will post 6.49 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.97%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. True Wealth Design LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $26,000. Coppell Advisory Solutions Corp. purchased a new position in Bristol-Myers Squibb during the fourth quarter worth about $31,000. Coppell Advisory Solutions LLC bought a new stake in Bristol-Myers Squibb in the 2nd quarter worth about $28,000. Live Oak Investment Partners purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $33,000. Finally, OFI Invest Asset Management bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $25,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.